[{"data":1,"prerenderedAt":25},["ShallowReactive",2],{"project-9756e76169f1c1cc002be88f10db24da":3},{"_id":4,"slug":4,"title":5,"subtitle":6,"cover":8,"tech_type":9,"indications":10,"official_price":11,"hospital_name":12,"hospital_names":13,"tech_company_name":14,"view_count":15,"favorite_count":16,"is_favorite":17,"approval_no":18,"approval_date":14,"regulatory_level":19,"valid_until":14,"filing_date":20,"intro":21,"detail_desc":14,"target_population":22,"compliance_list":23,"process":24},"9756e76169f1c1cc002be88f10db24da","2型糖尿病的人脐带间充质生物医学新技术",[7],"糖尿病","https://6875-huali-cell-8geyb3yje6a285d1-1419749029.tcb.qcloud.la/assets/cover/1778074643287-mmexport1778074598518.jpg","干细胞应用",[7],"5.8万/针起(3针/疗程)","2型糖尿病的人脐带间充质干细胞应用技术",[],"",384,1,false,"乐医药监〔2025〕113 号","低风险","2025年","适应症：基于现有的联合使用至少3种降糖药(包括胰岛素在内)血糖控制不佳的2型糖尿病患者",[],[],[],1779368115444]